• Home
  •  / Matinas BioPharma

Matinas BioPharma

OverviewSuggest Edit

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on the development of MAT9001, a candidate for the treatment of cardiovascular and metabolic conditions. The medication is an omega-3 fatty acid-based composition, comprised of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DPA), designed to overcome the shortcomings seen from other agents in the omega-3 class. In addition, the company develops MAT2203, a formulation of Amphotericin B designed to treat invasive fungal infections.
TypePublic
Founded2011
HQBedminster, USMap
Websitematinasbiopharma.com
View Jobs

Locations

Matinas BioPharma is headquartered in
Bedminster, United States

Location Map
All Locations (2)

Latest Updates

Employees (est.) (Mar 2020)21(+40%)
Revenue (FY, 2019)$89.8 K(-25%)
Share Price (Mar 2020)$0.7 (-7%)

Matinas BioPharma Office Locations

Matinas BioPharma has offices in Bedminster and Raritan
Bedminster, US (HQ)
1545 US-206 #302
Raritan, US
1025 US-202 206, 3rd floor
Show all (2)

Matinas BioPharma Financials and Metrics

Matinas BioPharma Revenue

Matinas BioPharma's revenue was reported to be $89.81 k in FY, 2019
USD

Revenue (FY, 2019)

89.8k

Net income (FY, 2019)

(17.4m)

EBIT (FY, 2019)

(18.9m)

Market capitalization (27-Mar-2020)

141.5m

Closing stock price (27-Mar-2020)

0.7

Cash (31-Dec-2019)

22.2m

EV

123.5m
Matinas BioPharma's current market capitalization is $141.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

194.5k149.7k119.8k89.8k

General and administrative expense

5.3m4.8m4.3m7.6m8.0m7.8m

R&D expense

5.2m5.3m3.9m9.0m6.8m11.2m

Operating expense total

10.5m10.1m8.3m16.7m14.8m19.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

59.9k15.0k44.9k44.9k29.9k89.8k89.8k

General and administrative expense

1.1m1.3m1.5m1.2m1.1m1.3m1.3m977.7k999.8k2.1m1.7m1.4m2.0m2.0m1.6m1.8m1.8m1.9m

R&D expense

1.1m1.1m1.1m1.4m1.4m879.2k921.7k642.6k835.3k2.4m2.3m2.0m2.2m1.5m1.4m2.3m2.8m2.7m

Operating expense total

2.1m2.4m2.6m2.6m2.5m2.2m2.2m1.6m1.8m4.5m4.0m3.5m4.2m3.5m3.0m4.1m4.6m4.6m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.6m3.2m4.1m7.3m12.4m22.2m

Prepaid Expenses

114.4k231.8k304.4k502.0k538.6k1.9m

Current Assets

2.8m3.6m4.6m8.0m13.1m29.9m

PP&E

340.0k377.7k356.1k1.6m2.0m1.7m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

8.6m6.6m5.0m4.6m6.6m4.4m1.7m578.3k6.2m15.8m11.3m9.0m4.3m8.9m6.6m39.4m36.8m32.7m

Accounts Receivable

89.8k

Prepaid Expenses

87.6k38.1k108.1k93.6k115.0k342.2k138.0k139.6k254.0k803.0k317.3k1.0m475.3k249.8k692.4k391.0k494.6k1.4m

Current Assets

8.6m6.7m5.1m4.8m6.9m4.9m1.9m773.5k6.5m16.8m11.7m10.2m4.9m9.3m7.5m39.9m37.4m34.3m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.2m)(9.1m)(7.6m)(15.5m)(14.1m)(17.4m)

Depreciation and Amortization

41.6k43.5k52.6k100.6k218.3k206.0k

Accounts Payable

(125.6k)(73.7k)(22.2k)107.3k(287.2k)383.7k

Cash From Operating Activities

(8.0m)(7.8m)(6.1m)(11.5m)(10.3m)(14.1m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(2.1m)(4.6m)(7.2m)(2.6m)(5.0m)(7.1m)(2.2m)(3.9m)(5.7m)(4.5m)(8.5m)(11.9m)(4.1m)(7.5m)(10.5m)(4.1m)(7.4m)(11.8m)

Depreciation and Amortization

9.5k19.9k51.5k10.9k20.6k32.7k12.9k26.3k40.0k12.0k24.8k56.2k47.1k100.1k156.6k47.9k96.9k148.9k

Accounts Payable

(154.4k)(115.7k)(184.9k)(104.9k)174.0k(289.5k)122.7k(22.0k)(288.4k)771.9k(22.4k)(134.0k)(109.4k)(85.5k)(279.4k)99.0k252.5k390.1k

Cash From Operating Activities

(2.1m)(3.9m)(5.5m)(2.3m)(4.5m)(6.7m)(1.5m)(2.6m)(4.0m)(3.0m)(6.8m)(9.5m)(2.8m)(5.1m)(7.7m)(3.0m)(5.1m)(9.2m)
show all
USDY, 2019

EV/EBIT

-6.5 x

EV/CFO

-8.8 x

Revenue/Employee

6.0k

Financial Leverage

1.2 x
Show all financial metrics

Matinas BioPharma Online and Social Media Presence

Matinas BioPharma's Trends

Embed Graph

 Matinas BioPharma Frequently Asked Questions

  • When was Matinas BioPharma founded?

    Matinas BioPharma was founded in 2011.

  • How many employees does Matinas BioPharma have?

    Matinas BioPharma has 21 employees.

  • What is Matinas BioPharma revenue?

    Latest Matinas BioPharma annual revenue is $89.8 k.

  • What is Matinas BioPharma revenue per employee?

    Latest Matinas BioPharma revenue per employee is $4.3 k.

  • Who are Matinas BioPharma competitors?

    Competitors of Matinas BioPharma include TG Therapeutics, Regulus Therapeutics and Dynavax Technologies.

  • Where is Matinas BioPharma headquarters?

    Matinas BioPharma headquarters is located at 1545 US-206 #302, Bedminster.

  • Where are Matinas BioPharma offices?

    Matinas BioPharma has offices in Bedminster and Raritan.

  • How many offices does Matinas BioPharma have?

    Matinas BioPharma has 2 offices.